Kim D, Kim J, Park YI, Lee N, Hyeon T
Growth and viability of macrophages continuously stimulated to produce nitric oxide
Developer: Eli Lilly and Company | Administration in Trials: Once-weekly subcutaneous injection First successful Phase 3 trial (TRIUMPH-4, topline Dec 2025): Up to 28.7% average body weight loss at 68 weeks (highest dose) in adults with obesity/overweight and knee osteoarthritis
L., Rizza, R
This is a triple-agonist medication that acts on three different hormone receptors in the body: glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide (GIP), and glucagon (GCG), Dr
Treating BED is not just about medicationfactors like biology, emotional eating, nutrition, and co-existing mental health conditions like depression, anxiety, substance use disorder, and obsessive-compulsive disorder (OCD) may cause binge eating disorder